Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood–brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas
Neuro-Oncology · 04.11.2024 · 26 (11) · 2044-2060
DOI: 10.1093/neuonc/noae135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 19.07.2024. Verfasst von Kwang-Soo Kim und 33 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, C…. Hauptthemen laut MEDLINE: Doxorubicin, Brain Neoplasms, Blood-Brain Barrier, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NINDS NIH HHS, Panattoni family.
Abstract (Originalsprache)
Background
Glioblastoma is a highly aggressive brain cancer that is resistant to conventional immunotherapy strategies. Botensilimab, an Fc-enhanced anti-CTLA-4 antibody (FcE-aCTLA-4), has shown durable activity in “cold” and immunotherapy-refractory cancers.
Methods
We evaluated the efficacy and immune microenvironment phenotype of a mouse analogue of FcE-aCTLA-4 in treatment-refractory preclinical models of glioblastoma, both as a monotherapy and in combination with doxorubicin delivered via low-intensity pulsed ultrasound and microbubbles (LIPU/MB). Additionally, we studied 4 glioblastoma patients treated with doxorubicin, anti-PD-1 with concomitant LIPU/MB to investigate the novel effect of doxorubicin modulating FcγR expressions in tumor-associated macrophages/microglia (TAMs).
Results
FcE-aCTLA-4 demonstrated high-affinity binding to FcγRIV, the mouse ortholog of human FcγRIIIA, which was highly expressed in TAMs in human glioblastoma, most robustly at diagnosis. Notably, FcE-aCTLA-4-mediated selective depletion of intratumoral regulatory T cells (Tregs) via TAM-mediated phagocytosis, while sparing peripheral Tregs. Doxorubicin, a chemotherapeutic drug with immunomodulatory functions, was found to upregulate FcγRIIIA on TAMs in glioblastoma patients who received doxorubicin and anti-PD-1 with concomitant LIPU/MB. In murine models of immunotherapy-resistant gliomas, a combinatorial regimen of FcE-aCTLA-4, anti-PD-1, and doxorubicin with LIPU/MB, achieved a 90% cure rate, that was associated robust infiltration of activated CD8+ T cells and establishment of immunological memory as evidenced by rejection upon tumor rechallenge.
Conclusions
Our findings demonstrate that FcE-aCTLA-4 promotes robust immunomodulatory and anti-tumor effects in murine gliomas and is significantly enhanced when combined with anti-PD-1, doxorubicin, and LIPU/MB. We are currently investigating this combinatory strategy in a clinical trial (clinicaltrials.gov NCT05864534).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
- Department of Neurological Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
- Department of Biomedical Informatics, Columbia University, New York, New York, USA.
- Program for Mathematical Genomics, Department of Systems Biology, Columbia University, New York, New York, USA.
- Department of Systems Biology, Columbia University, New York, New York, USA.
- Agenus Inc., Lexington, Massachusetts, USA.
ORCID-Profile: Raul Rabadan, Roger Stupp, Catalina Lee-Chang, Adam M Sonabend
Förderung
- NCI NIH HHS
- NINDS NIH HHS
- Panattoni family
- SPORE
- NIH HHS
- Vagelos Precision Medicine
- Moceri Family Foundation
- NIH
Zitieren
APA
Kim, K. S., Habashy, K., Gould, A., Zhao, J., Najem, H., Amidei, C., Saganty, R., Arrieta, V. A., Dmello, C., Chen, L., Zhang, D. Y., Castro, B., Billingham, L., Levey, D., Huber, O., Marques, M., Savitsky, D. A., Morin, B. M., Muzzio, M., …, & Sonabend, A. M. (2024). Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood–brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas. Neuro-Oncology, 26(11), 2044-2060. https://doi.org/10.1093/neuonc/noae135
Vancouver
Kim KS, Habashy K, Gould A, Zhao J, Najem H, Amidei C, et al. Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood–brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas. Neuro-Oncology. 2024;26(11):2044-2060. doi:10.1093/neuonc/noae135
BibTeX
@article{Kim2024,
author = {Kim, Kwang-Soo and Habashy, Karl and Gould, Andrew and Zhao, Junfei and Najem, Hinda and Amidei, Christina and Saganty, Ruth and Arrieta, Víctor A and Dmello, Crismita and Chen, Li and Zhang, Daniel Y and Castro, Brandyn and Billingham, Leah and Levey, Daniel and Huber, Olivia and Marques, Marilyn and Savitsky, David A and Morin, Benjamin M and Muzzio, Miguel and Canney, Michael and Horbinski, Craig and Zhang, Peng and Miska, Jason and Padney, Surya and Zhang, Bin and Rabadan, Raul and Phillips, Joanna J and Butowski, Nicholas and Heimberger, Amy B and Hu, Jian and Stupp, Roger and Chand, Dhan and Lee-Chang, Catalina and Sonabend, Adam M},
title = {Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood–brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas},
journal = {Neuro-Oncology},
year = {2024},
volume = {26},
number = {11},
pages = {2044--2060},
doi = {10.1093/neuonc/noae135}
}
EUVIMED